Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ArriVent BioPharma, Inc.AVBP · Entity 4699 | Director | January 25, 2024 | January 29, 2024 |
| Elevance Health, Inc.ELV · Entity 2934 | Director | May 13, 2026 | May 15, 2026 |
| Guardant Health, Inc.GH · Entity 3238 | Director | June 15, 2022 | June 17, 2022 |
| Immunocore Holdings plcIMCR · Entity 4544 | Director · CHIEF EXECUTIVE OFFICER | February 17, 2026 | February 19, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ArriVent BioPharma, Inc.
Report date January 25, 2024 · Filed January 29, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.00 · Expires 2034-01-24 | Direct | 17,884 |
Reported balance
After 2024-01-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-01-25 · Grant · Acquired 17,884 · Balance 17,884 F1: These options vest on the first anniversary of the grant date, subject to the Reporting Person's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: These options vest on the first anniversary of the grant date, subject to the Reporting Person's continued service through the applicable vesting date.
Elevance Health, Inc.
Report date May 13, 2026 · Filed May 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,351 |
Reported balance
After 2026-05-13 transaction · row 1
1 source rowRow 1 · 2026-05-13 · Grant · Acquired 563 · Balance 5,351 F1: Deferred stock units accrued under the Elevance Health, Inc. ("Company") Board of Directors Compensation Program. F2: The deferred stock units shall be payable in Company common stock upon the first to occur of (a) five years from the date of grant or (b) the date the Reporting Person ceases to be a member of the Company's board of directors, unless a later date is designated in the Reporting Person's election made under the Company's Board of Directors Deferred Compensation Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Deferred stock units accrued under the Elevance Health, Inc. ("Company") Board of Directors Compensation Program.
F2: The deferred stock units shall be payable in Company common stock upon the first to occur of (a) five years from the date of grant or (b) the date the Reporting Person ceases to be a member of the Company's board of directors, unless a later date is designated in the Reporting Person's election made under the Company's Board of Directors Deferred Compensation Plan.
Guardant Health, Inc.
Report date June 15, 2022 · Filed June 17, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| COMMON STOCKSEC Table I · non-derivative | Direct | 7,408 |
Reported balance
After 2022-06-15 transaction · row 1
1 source rowRow 1 · 2022-06-15 · Exercise / conversion · Acquired 1,814 · Balance 7,408 |
| RESTRICTED STOCK UNITSSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2022-06-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-06-15 · Exercise / conversion · Disposed 1,814 · Balance 0 F1: The Restricted Stock Units vest in full on the one-year anniversary of the grant date, June 15th, 2022. F2: Not applicable for Restricted Stock Units. |
Filing footnotes · ownership attribution and instrument terms
F1: The Restricted Stock Units vest in full on the one-year anniversary of the grant date, June 15th, 2022.
F2: Not applicable for Restricted Stock Units.
Immunocore Holdings plc
Report date February 17, 2026 · Filed February 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 12,343 |
Last balance in matching sequence
After 2026-02-18 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-02-17 · Exercise / conversion · Acquired 23,817 · Balance 23,817 F1: Ordinary Shares may be represented by American Depositary Shares. Each American Depositary Share represents one Ordinary Share. Row 2 · 2026-02-18 · Sale · Disposed 11,474 · Balance 12,343 F1: Ordinary Shares may be represented by American Depositary Shares. Each American Depositary Share represents one Ordinary Share. F2: The shares were sold pursuant to a sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted share units ("RSUs"). F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.17 to $32.70 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 71,453 |
Reported balance
After 2026-02-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-17 · Exercise / conversion · Disposed 23,817 · Balance 71,453 F4: Each RSU represents a contingent right to receive one Ordinary Share. F5: On February 17, 2025, the Reporting Person was granted 95,270 RSUs, vesting in four equal annual installments beginning February 17, 2026, subject to the Reporting Person's continuous service through each such vesting date. F1: Ordinary Shares may be represented by American Depositary Shares. Each American Depositary Share represents one Ordinary Share. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 88,573 |
Reported balance
After 2026-02-17 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-02-17 · Grant · Acquired 88,573 · Balance 88,573 F4: Each RSU represents a contingent right to receive one Ordinary Share. F6: The RSUs vest in four equal annual installments beginning February 17, 2027, subject to the Reporting Person's continuous service through each such vesting date. F1: Ordinary Shares may be represented by American Depositary Shares. Each American Depositary Share represents one Ordinary Share. |
| Employee Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $32.38 · Expires 2036-02-16 | Direct | 395,066 |
Reported balance
After 2026-02-17 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-02-17 · Grant · Acquired 395,066 · Balance 395,066 F7: 25% of the shares subject to the option award shall vest on February 17, 2027, and 6.25% of the shares subject to the option award shall vest in quarterly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. F1: Ordinary Shares may be represented by American Depositary Shares. Each American Depositary Share represents one Ordinary Share. |
Filing footnotes · ownership attribution and instrument terms
F1: Ordinary Shares may be represented by American Depositary Shares. Each American Depositary Share represents one Ordinary Share.
F2: The shares were sold pursuant to a sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted share units ("RSUs").
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.17 to $32.70 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: Each RSU represents a contingent right to receive one Ordinary Share.
F5: On February 17, 2025, the Reporting Person was granted 95,270 RSUs, vesting in four equal annual installments beginning February 17, 2026, subject to the Reporting Person's continuous service through each such vesting date.
F6: The RSUs vest in four equal annual installments beginning February 17, 2027, subject to the Reporting Person's continuous service through each such vesting date.
F7: 25% of the shares subject to the option award shall vest on February 17, 2027, and 6.25% of the shares subject to the option award shall vest in quarterly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 13, 2026 Filed May 15, 2026 20:14 UTC | Elevance Health, Inc. ELV · Entity 2934 | GrantCommon Stock | 563 | $0.00 | $0.00 |
DisclosureSEC source: 0001730038-26-000004 · wk-form4_1778876036.xml · nonDerivative · entry 1 Jallal Bahija · CIK 0001730038 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,351 F1 · shares: Deferred stock units accrued under the Elevance Health, Inc. ("Company") Board of Directors Compensation Program. F2 · shares: The deferred stock units shall be payable in Company common stock upon the first to occur of (a) five years from the date of grant or (b) the date the Reporting Person ceases to be a member of the Company's board of directors, unless a later date is designated in the Reporting Person's election made under the Company's Board of Directors Deferred Compensation Plan. Read SEC document |
| February 18, 2026 Filed Feb 19, 2026 22:00 UTC | Immunocore Holdings plc IMCR · Entity 4544 | SaleOrdinary Shares | 11,474 | $32.35 | $371,183.90 |
DisclosureSEC source: 0001730038-26-000002 · form4-02192026_050209.xml · nonDerivative · entry 2 Jallal Bahija · CIK 0001730038 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,343 F1 · security: Ordinary Shares may be represented by American Depositary Shares. Each American Depositary Share represents one Ordinary Share. F2 · shares: The shares were sold pursuant to a sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted share units ("RSUs"). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.17 to $32.70 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 22:00 UTC | Immunocore Holdings plc IMCR · Entity 4544 | GrantEmployee Share Option (Right to Buy) · Derivative | 395,066 | $0.00 Strike: $32.38 | $0.00 |
DisclosureSEC source: 0001730038-26-000002 · form4-02192026_050209.xml · derivative · entry 5 Jallal Bahija · CIK 0001730038 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 395,066 Underlying: Ordinary Shares · 395,066 shares Expires 2036-02-16 F7 · derivative.exercise_date: 25% of the shares subject to the option award shall vest on February 17, 2027, and 6.25% of the shares subject to the option award shall vest in quarterly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. F1 · derivative.underlying: Ordinary Shares may be represented by American Depositary Shares. Each American Depositary Share represents one Ordinary Share. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 22:00 UTC | Immunocore Holdings plc IMCR · Entity 4544 | GrantRestricted Share Units · Derivative | 88,573 | $0.00 | $0.00 |
DisclosureSEC source: 0001730038-26-000002 · form4-02192026_050209.xml · derivative · entry 4 Jallal Bahija · CIK 0001730038 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,573 Underlying: Ordinary Shares · 88,573 shares Expires not disclosed F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one Ordinary Share. F6 · derivative.exercise_date: The RSUs vest in four equal annual installments beginning February 17, 2027, subject to the Reporting Person's continuous service through each such vesting date. F6 · derivative.expiration_date: The RSUs vest in four equal annual installments beginning February 17, 2027, subject to the Reporting Person's continuous service through each such vesting date. F1 · derivative.underlying: Ordinary Shares may be represented by American Depositary Shares. Each American Depositary Share represents one Ordinary Share. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 22:00 UTC | Immunocore Holdings plc IMCR · Entity 4544 | Exercise / conversionRestricted Share Units · Derivative | 23,817 | $0.00 | $0.00 |
DisclosureSEC source: 0001730038-26-000002 · form4-02192026_050209.xml · derivative · entry 3 Jallal Bahija · CIK 0001730038 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,453 Underlying: Ordinary Shares · 23,817 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one Ordinary Share. F5 · derivative.exercise_date: On February 17, 2025, the Reporting Person was granted 95,270 RSUs, vesting in four equal annual installments beginning February 17, 2026, subject to the Reporting Person's continuous service through each such vesting date. F5 · derivative.expiration_date: On February 17, 2025, the Reporting Person was granted 95,270 RSUs, vesting in four equal annual installments beginning February 17, 2026, subject to the Reporting Person's continuous service through each such vesting date. F1 · derivative.underlying: Ordinary Shares may be represented by American Depositary Shares. Each American Depositary Share represents one Ordinary Share. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 22:00 UTC | Immunocore Holdings plc IMCR · Entity 4544 | Exercise / conversionOrdinary Shares | 23,817 | $0.00 | $0.00 |
DisclosureSEC source: 0001730038-26-000002 · form4-02192026_050209.xml · nonDerivative · entry 1 Jallal Bahija · CIK 0001730038 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,817 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Ordinary Shares may be represented by American Depositary Shares. Each American Depositary Share represents one Ordinary Share. Read SEC document |
| May 14, 2025 Filed May 16, 2025 20:17 UTC | Elevance Health, Inc. ELV · Entity 2934 | GrantCommon Stock | 601 | $0.00 | $0.00 |
DisclosureSEC source: 0001156039-25-000088 · wk-form4_1747426626.xml · nonDerivative · entry 1 Jallal Bahija · CIK 0001730038 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,788 F1 · shares: Deferred stock units accrued under the Elevance Health, Inc. ("Company") Board of Directors Compensation Program. F2 · shares: The deferred stock units shall be payable in Company common stock upon the first to occur of (a) five years from the date of grant or (b) the date the Reporting Person ceases to be a member of the Company's board of directors, unless a later date is designated in the Reporting Person's election made under the Company's Board of Directors Deferred Compensation Plan. Read SEC document |
| February 17, 2025 Filed Feb 19, 2025 21:17 UTC | Immunocore Holdings plc IMCR · Entity 4544 | GrantRestricted Share Units · Derivative | 95,270 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004602 · form4-02192025_090204.xml · derivative · entry 2 Jallal Bahija · CIK 0001730038 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,270 Underlying: Ordinary Shares · 95,270 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit ("RSU") represents a contingent right to receive one ordinary share. F3 · derivative.exercise_date: The RSUs vest in four equal annual installments beginning February 17, 2026, subject to the Reporting Person's continuous service through each such vesting date. F3 · derivative.expiration_date: The RSUs vest in four equal annual installments beginning February 17, 2026, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| February 17, 2025 Filed Feb 19, 2025 21:17 UTC | Immunocore Holdings plc IMCR · Entity 4544 | GrantEmployee Share Option (Right to Buy) · Derivative | 405,824 | $0.00 Strike: $29.60 | $0.00 |
DisclosureSEC source: 0001415889-25-004602 · form4-02192025_090204.xml · derivative · entry 1 Jallal Bahija · CIK 0001730038 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 405,824 Underlying: Ordinary Shares · 405,824 shares Expires 2035-02-16 F1 · derivative.exercise_date: 25% of the shares subject to the option award shall vest on February 17, 2026, and 6.25% of the shares subject to the option award shall vest in quarterly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| May 15, 2024 Filed May 17, 2024 20:23 UTC | Elevance Health, Inc. ELV · Entity 2934 | GrantCommon Stock | 388 | $0.00 | $0.00 |
DisclosureSEC source: 0001156039-24-000084 · wk-form4_1715977369.xml · nonDerivative · entry 1 Jallal Bahija · CIK 0001730038 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,187 F1 · shares: Deferred stock units accrued under the Elevance Health, Inc. ("Company") Board of Directors Compensation Program. F2 · shares: The deferred stock units shall be payable in Company common stock upon the first to occur of (a) five years from the date of grant or (b) the date the Reporting Person ceases to be a member of the Company's board of directors, unless a later date is designated in the Reporting Person's election made under the Company's Board of Directors Deferred Compensation Plan. Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 21:15 UTC | Immunocore Holdings plc IMCR · Entity 4544 | GrantEmployee Share Option (Right to Buy) · Derivative | 281,819 | $0.00 Strike: $70.50 | $0.00 |
DisclosureSEC source: 0001415889-24-004590 · form4-02212024_040209.xml · derivative · entry 1 Jallal Bahija · CIK 0001730038 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 281,819 Underlying: Ordinary Shares · 281,819 shares Expires 2034-02-15 F1 · derivative.exercise_date: 25% of the shares subject to the option award shall vest on February 16, 2025, and 6.25% of the shares subject to the option award shall vest in quarterly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| January 25, 2024 Filed Jan 29, 2024 21:15 UTC | ArriVent BioPharma, Inc. AVBP · Entity 4699 | GrantStock Option (right to buy) · Derivative | 17,884 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001104659-24-007732 · tm244377-1_4seq1.xml · derivative · entry 1 Jallal Bahija · CIK 0001730038 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,884 Underlying: Common Stock · 17,884 shares Expires 2034-01-24 F1 · derivative.exercise_date: These options vest on the first anniversary of the grant date, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| May 10, 2023 Filed May 12, 2023 20:21 UTC | Elevance Health, Inc. ELV · Entity 2934 | GrantCommon Stock | 457 | $0.00 | $0.00 |
DisclosureSEC source: 0001156039-23-000072 · wf-form4_168392290042931.xml · nonDerivative · entry 1 Jallal Bahija · CIK 0001730038 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,799 F1 · shares: Deferred stock units accrued under the Elevance Health, Inc. ("Company") Board of Directors Compensation Program. F2 · shares: The deferred stock units shall be payable in Company common stock upon the first to occur of (a) five years from the date of grant or (b) the date the Reporting Person ceases to be a member of the Company's board of directors, unless a later date is designated in the Reporting Person's election made under the Company's Board of Directors Deferred Compensation Plan. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 22:03 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRESTRICTED STOCK UNITS · Derivative | 1,814 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001576280-22-000046 · wf-form4_165550336542100.xml · derivative · entry 2 Jallal Bahija · CIK 0001730038 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: COMMON STOCK · 1,814 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The Restricted Stock Units vest in full on the one-year anniversary of the grant date, June 15th, 2022. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 22:03 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCOMMON STOCK | 1,814 | $0.00 | $0.00 |
DisclosureSEC source: 0001576280-22-000046 · wf-form4_165550336542100.xml · nonDerivative · entry 1 Jallal Bahija · CIK 0001730038 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,408 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 18, 2022 Filed May 20, 2022 20:48 UTC | Elevance Health, Inc. ANTM · Entity 2934 | GrantCommon Stock | 440 | $0.00 | $0.00 |
DisclosureSEC source: 0001156039-22-000062 · wf-form4_165307967082290.xml · nonDerivative · entry 1 Jallal Bahija · CIK 0001730038 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,342 F1 · shares: Phantom Stock units accrued under the Anthem, Inc. ("Company") Board of Directors Compensation Program. F2 · shares: The phantom stock units shall be payable in Company common stock upon the first to occur of (a) five years from the date of grant or (b) the date the Reporting Person ceases to be a member of the Company's board of directors, unless a later date is designated in the Reporting Person's election made under the Company's Board of Directors Deferred Compensation Plan. Read SEC document |
| June 16, 2021 Filed Jun 21, 2021 21:26 UTC | Guardant Health, Inc. GH · Entity 3238 | GrantRESTRICTED STOCK UNITS · Derivative | 1,814 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001576280-21-000071 · wf-form4_162431075861171.xml · derivative · entry 2 Jallal Bahija · CIK 0001730038 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,814 Underlying: COMMON STOCK · 1,814 shares Expires not disclosed F2 · derivative.exercise_date: The restricted stock units vest in full on the one-year anniversary of the grant date, June 16th, 2022. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| June 16, 2021 Filed Jun 21, 2021 21:26 UTC | Guardant Health, Inc. GH · Entity 3238 | GrantSTOCK OPTION (RIGHT TO BUY) · Derivative | 3,135 | $0.00 Strike: $117.19 | $0.00 |
DisclosureSEC source: 0001576280-21-000071 · wf-form4_162431075861171.xml · derivative · entry 1 Jallal Bahija · CIK 0001730038 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,135 Underlying: COMMON STOCK · 3,135 shares Expires 2031-06-15 F1 · derivative.exercise_date: The stock option vests in full on the one-year anniversary of the grant date, June 16th, 2022. Read SEC document |
| May 26, 2021 Filed May 28, 2021 20:30 UTC | Elevance Health, Inc. ANTM · Entity 2934 | GrantCommon Stock | 493 | $0.00 | $0.00 |
DisclosureSEC source: 0001156039-21-000060 · wf-form4_162223381300697.xml · nonDerivative · entry 1 Jallal Bahija · CIK 0001730038 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,902 F1 · shares: Phantom Stock units accrued under the Anthem, Inc. ("Company") Board of Directors Compensation Program. F2 · shares: The phantom stock units shall be payable in Company common stock upon the first to occur of (a) five years from the date of grant or (b) the date the Reporting Person ceases to be a member of the Company's board of directors, unless a later date is designated in the Reporting Person's election made under the Company's Board of Directors Deferred Compensation Plan. Read SEC document |
| June 12, 2020 Filed Jun 16, 2020 21:55 UTC | Guardant Health, Inc. GH · Entity 3238 | GrantSTOCK OPTION (RIGHT TO BUY) · Derivative | 4,840 | $0.00 Strike: $77.09 | $0.00 |
DisclosureSEC source: 0001628280-20-009562 · wf-form4_159234452903713.xml · derivative · entry 2 Jallal Bahija · CIK 0001730038 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,840 Underlying: COMMON STOCK · 4,840 shares Expires 2030-06-11 F1 · derivative.exercise_date: The stock option vests in full on the earlier to occur of (i) June 12, 2021 and (ii) the date of the next annual meeting of the Issuer's stockholders. Read SEC document |
| June 12, 2020 Filed Jun 16, 2020 21:55 UTC | Guardant Health, Inc. GH · Entity 3238 | GrantCOMMON STOCK | 2,757 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-20-009562 · wf-form4_159234452903713.xml · nonDerivative · entry 1 Jallal Bahija · CIK 0001730038 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,594 Read SEC document |
| May 21, 2020 Filed May 26, 2020 20:34 UTC | Elevance Health, Inc. ANTM · Entity 2934 | GrantCommon Stock | 699 | $0.00 | $0.00 |
DisclosureSEC source: 0001156039-20-000046 · wf-form4_159052525807174.xml · nonDerivative · entry 1 Jallal Bahija · CIK 0001730038 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,409 F1 · shares: Phantom Stock units accrued under the Anthem, Inc. ("Company") Board of Directors Compensation Program. F2 · shares: The phantom stock units shall be payable in Company common stock upon the first to occur of (a) five years from the date of grant or (b) the date the Reporting Person ceases to be a member of the Company's board of directors, unless a later date is designated in the Reporting Person's election made under the Company's Board of Directors Deferred Compensation Plan. Read SEC document |
| May 15, 2019 Filed May 17, 2019 20:15 UTC | Elevance Health, Inc. ANTM · Entity 2934 | GrantCommon Stock | 753 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-018989 · form4.xml · nonDerivative · entry 1 Jallal Bahija · CIK 0001730038 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,710 F1 · shares: Phantom Stock units accrued under the Anthem, Inc. ("Company") Board of Directors Compensation Program. F2 · shares: The phantom stock units shall be payable in Company common stock upon the first to occur of (a) five years from the date of grant or (b) the date the Reporting Person ceases to be a member of the Company's board of directors, unless a later date is designated in the Reporting Person's election made under the Company's Board of Directors Deferred Compensation Plan. Read SEC document |
| April 17, 2019 Filed Apr 19, 2019 22:40 UTC | Guardant Health, Inc. GH · Entity 3238 | GrantSTOCK OPTION (RIGHT TO BUY) · Derivative | 4,526 | $0.00 Strike: $72.71 | $0.00 |
DisclosureSEC source: 0001628280-19-004540 · wf-form4_155571362598381.xml · derivative · entry 2 Jallal Bahija · CIK 0001730038 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,526 Underlying: COMMON STOCK · 4,526 shares Expires 2029-04-16 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in equal annual installments over 3 years commencing on April 17, 2019. Read SEC document |
| April 17, 2019 Filed Apr 19, 2019 22:40 UTC | Guardant Health, Inc. GH · Entity 3238 | GrantCOMMON STOCK | 2,837 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-19-004540 · wf-form4_155571362598381.xml · nonDerivative · entry 1 Jallal Bahija · CIK 0001730038 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,837 Read SEC document |
| May 16, 2018 Filed May 18, 2018 20:23 UTC | Elevance Health, Inc. ANTM · Entity 2934 | GrantCommon Stock | 753 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-018136 · form4.xml · nonDerivative · entry 1 Jallal Bahija · CIK 0001730038 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 957 F1 · shares: Phantom Stock units accrued under the Anthem, Inc. ("Company") Board of Directors Compensation Program. F2 · shares: The phantom stock units shall be payable in Company common stock upon the first to occur of (a) five years from the date of grant or (b) the date the Reporting Person ceases to be a member of the Company's board of directors, unless a later date is designated in the Reporting Person's election made under the Company's Board of Directors Deferred Compensation Plan. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 21:41 UTC | Elevance Health, Inc. ANTM · Entity 2934 | GrantCommon Stock | 204 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-004013 · form4.xml · nonDerivative · entry 1 Jallal Bahija · CIK 0001730038 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204 F1 · shares: Phantom Stock units accrued under the Anthem, Inc. ("Company") Board of Directors Compensation Program. F2 · shares: The phantom stock units shall be payable in Company common stock upon the first to occur of (a) five years from the date of grant or (b) the date the Reporting Person ceases to be a member of the Company's board of directors, unless a later date is designated in the Reporting Person's election made under the Company's Board of Directors Deferred Compensation Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.